Search research articles
Contact Us
Filters
Showing results (131-140 of 176) with videos related to
Page
of 18
Sort By:
Nature Medicine
|
February 5, 2024
Publisher Correction: Advancing T cell-based cancer therapy with single-cell technologies
Samantha L Bucktrout, Nicholas E Banovich, Lisa H Butterfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
Lisa H Butterfield, Antoni Ribas, Vivian B Dissette, et al.
Cancer Immunology Research
|
May 20, 2017
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, et al.
Cytotherapy
|
September 3, 2017
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis, Mounzer Agha, Robert L Redner, et al.
Clinical Trials (London, England)
|
July 7, 2011
Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned
Jennifer Steel, David A Geller, Allan Tsung, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2018
Immune oncology, immune responsiveness and the theory of everything
Tolga Turan, Deepti Kannan, Maulik Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC
Hideho Okada, Lisa H Butterfield, Ronald L Hamilton, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Systematic evaluation of immune regulation and modulation
David F Stroncek, Lisa H Butterfield, Michael A Cannarile, et al.
Cancer
|
October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 176) with videos related to
Sort By:
Page
of 18
Nature Medicine
|
February 5, 2024
Publisher Correction: Advancing T cell-based cancer therapy with single-cell technologies
Samantha L Bucktrout, Nicholas E Banovich, Lisa H Butterfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
Lisa H Butterfield, Antoni Ribas, Vivian B Dissette, et al.
Cancer Immunology Research
|
May 20, 2017
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, et al.
Cytotherapy
|
September 3, 2017
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis, Mounzer Agha, Robert L Redner, et al.
Clinical Trials (London, England)
|
July 7, 2011
Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned
Jennifer Steel, David A Geller, Allan Tsung, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2018
Immune oncology, immune responsiveness and the theory of everything
Tolga Turan, Deepti Kannan, Maulik Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC
Hideho Okada, Lisa H Butterfield, Ronald L Hamilton, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Systematic evaluation of immune regulation and modulation
David F Stroncek, Lisa H Butterfield, Michael A Cannarile, et al.
Cancer
|
October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.
Page
of 18